The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.
<h4>Background</h4>Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs. The objective of our study was to forecast the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretro...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS Medicine |
| Online Access: | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004325&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849468937443475456 |
|---|---|
| author | Keri N Althoff Cameron Stewart Elizabeth Humes Lucas Gerace Cynthia Boyd Kelly Gebo Amy C Justice Emily P Hyle Sally B Coburn Raynell Lang Michael J Silverberg Michael A Horberg Viviane D Lima M John Gill Maile Karris Peter F Rebeiro Jennifer Thorne Ashleigh J Rich Heidi Crane Mari Kitahata Anna Rubtsova Cherise Wong Sean Leng Vincent C Marconi Gypsyamber D'Souza Hyang Nina Kim Sonia Napravnik Kathleen McGinnis Gregory D Kirk Timothy R Sterling Richard D Moore Parastu Kasaie |
| author_facet | Keri N Althoff Cameron Stewart Elizabeth Humes Lucas Gerace Cynthia Boyd Kelly Gebo Amy C Justice Emily P Hyle Sally B Coburn Raynell Lang Michael J Silverberg Michael A Horberg Viviane D Lima M John Gill Maile Karris Peter F Rebeiro Jennifer Thorne Ashleigh J Rich Heidi Crane Mari Kitahata Anna Rubtsova Cherise Wong Sean Leng Vincent C Marconi Gypsyamber D'Souza Hyang Nina Kim Sonia Napravnik Kathleen McGinnis Gregory D Kirk Timothy R Sterling Richard D Moore Parastu Kasaie |
| author_sort | Keri N Althoff |
| collection | DOAJ |
| description | <h4>Background</h4>Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs. The objective of our study was to forecast the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretroviral therapy (ART) in the United States (US) through 2030.<h4>Methods and findings</h4>Using the PEARL model-an agent-based simulation of PWH who have initiated ART in the US-the prevalence of anxiety, depression, stage ≥3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI), and multimorbidity (≥2 mental or physical comorbidities, other than HIV) were forecasted through 2030. Simulations were informed by the US CDC HIV surveillance data of new HIV diagnosis and the longitudinal North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) data on risk of comorbidities from 2009 to 2017. The simulated population represented 15 subgroups of PWH including Hispanic, non-Hispanic White (White), and non-Hispanic Black/African American (Black/AA) men who have sex with men (MSM), men and women with history of injection drug use and heterosexual men and women. Simulations were replicated for 200 runs and forecasted outcomes are presented as median values (95% uncertainty ranges are presented in the Supporting information). In 2020, PEARL forecasted a median population of 670,000 individuals receiving ART in the US, of whom 9% men and 4% women with history of injection drug use, 60% MSM, 8% heterosexual men, and 19% heterosexual women. Additionally, 44% were Black/AA, 32% White, and 23% Hispanic. Along with a gradual rise in population size of PWH receiving ART-reaching 908,000 individuals by 2030-PEARL forecasted a surge in prevalence of most comorbidities to 2030. Depression and/or anxiety was high and increased from 60% in 2020 to 64% in 2030. Hypertension decreased while dyslipidemia, diabetes, CKD, and MI increased. There was little change in prevalence of cancer and ESLD. The forecasted multimorbidity among PWH receiving ART increased from 63% in 2020 to 70% in 2030. There was heterogeneity in trends across subgroups. Among Black women with history of injection drug use in 2030 (oldest demographic subgroup with median age of 66 year), dyslipidemia, CKD, hypertension, diabetes, anxiety, and depression were most prevalent, with 92% experiencing multimorbidity. Among Black MSM in 2030 (youngest demographic subgroup with median age of 42 year), depression and CKD were highly prevalent, with 57% experiencing multimorbidity. These results are limited by the assumption that trends in new HIV diagnoses, mortality, and comorbidity risk observed in 2009 to 2017 will persist through 2030; influences occurring outside this period are not accounted for in the forecasts.<h4>Conclusions</h4>The PEARL forecasts suggest a continued rise in comorbidity and multimorbidity prevalence to 2030, marked by heterogeneities across race/ethnicity, gender, and HIV acquisition risk subgroups. HIV clinicians must stay current on the ever-changing comorbidities-specific guidelines to provide guideline-recommended care. HIV clinical directors should ensure linkages to subspecialty care within the clinic or by referral. HIV policy decision-makers must allocate resources and support extended clinical capacity to meet the healthcare needs of people aging with HIV. |
| format | Article |
| id | doaj-art-d4f574b3c0824d7b8e8524867b550270 |
| institution | Kabale University |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-d4f574b3c0824d7b8e8524867b5502702025-08-20T03:25:42ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762024-01-01211e100432510.1371/journal.pmed.1004325The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study.Keri N AlthoffCameron StewartElizabeth HumesLucas GeraceCynthia BoydKelly GeboAmy C JusticeEmily P HyleSally B CoburnRaynell LangMichael J SilverbergMichael A HorbergViviane D LimaM John GillMaile KarrisPeter F RebeiroJennifer ThorneAshleigh J RichHeidi CraneMari KitahataAnna RubtsovaCherise WongSean LengVincent C MarconiGypsyamber D'SouzaHyang Nina KimSonia NapravnikKathleen McGinnisGregory D KirkTimothy R SterlingRichard D MooreParastu Kasaie<h4>Background</h4>Estimating the medical complexity of people aging with HIV can inform clinical programs and policy to meet future healthcare needs. The objective of our study was to forecast the prevalence of comorbidities and multimorbidity among people with HIV (PWH) using antiretroviral therapy (ART) in the United States (US) through 2030.<h4>Methods and findings</h4>Using the PEARL model-an agent-based simulation of PWH who have initiated ART in the US-the prevalence of anxiety, depression, stage ≥3 chronic kidney disease (CKD), dyslipidemia, diabetes, hypertension, cancer, end-stage liver disease (ESLD), myocardial infarction (MI), and multimorbidity (≥2 mental or physical comorbidities, other than HIV) were forecasted through 2030. Simulations were informed by the US CDC HIV surveillance data of new HIV diagnosis and the longitudinal North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) data on risk of comorbidities from 2009 to 2017. The simulated population represented 15 subgroups of PWH including Hispanic, non-Hispanic White (White), and non-Hispanic Black/African American (Black/AA) men who have sex with men (MSM), men and women with history of injection drug use and heterosexual men and women. Simulations were replicated for 200 runs and forecasted outcomes are presented as median values (95% uncertainty ranges are presented in the Supporting information). In 2020, PEARL forecasted a median population of 670,000 individuals receiving ART in the US, of whom 9% men and 4% women with history of injection drug use, 60% MSM, 8% heterosexual men, and 19% heterosexual women. Additionally, 44% were Black/AA, 32% White, and 23% Hispanic. Along with a gradual rise in population size of PWH receiving ART-reaching 908,000 individuals by 2030-PEARL forecasted a surge in prevalence of most comorbidities to 2030. Depression and/or anxiety was high and increased from 60% in 2020 to 64% in 2030. Hypertension decreased while dyslipidemia, diabetes, CKD, and MI increased. There was little change in prevalence of cancer and ESLD. The forecasted multimorbidity among PWH receiving ART increased from 63% in 2020 to 70% in 2030. There was heterogeneity in trends across subgroups. Among Black women with history of injection drug use in 2030 (oldest demographic subgroup with median age of 66 year), dyslipidemia, CKD, hypertension, diabetes, anxiety, and depression were most prevalent, with 92% experiencing multimorbidity. Among Black MSM in 2030 (youngest demographic subgroup with median age of 42 year), depression and CKD were highly prevalent, with 57% experiencing multimorbidity. These results are limited by the assumption that trends in new HIV diagnoses, mortality, and comorbidity risk observed in 2009 to 2017 will persist through 2030; influences occurring outside this period are not accounted for in the forecasts.<h4>Conclusions</h4>The PEARL forecasts suggest a continued rise in comorbidity and multimorbidity prevalence to 2030, marked by heterogeneities across race/ethnicity, gender, and HIV acquisition risk subgroups. HIV clinicians must stay current on the ever-changing comorbidities-specific guidelines to provide guideline-recommended care. HIV clinical directors should ensure linkages to subspecialty care within the clinic or by referral. HIV policy decision-makers must allocate resources and support extended clinical capacity to meet the healthcare needs of people aging with HIV.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004325&type=printable |
| spellingShingle | Keri N Althoff Cameron Stewart Elizabeth Humes Lucas Gerace Cynthia Boyd Kelly Gebo Amy C Justice Emily P Hyle Sally B Coburn Raynell Lang Michael J Silverberg Michael A Horberg Viviane D Lima M John Gill Maile Karris Peter F Rebeiro Jennifer Thorne Ashleigh J Rich Heidi Crane Mari Kitahata Anna Rubtsova Cherise Wong Sean Leng Vincent C Marconi Gypsyamber D'Souza Hyang Nina Kim Sonia Napravnik Kathleen McGinnis Gregory D Kirk Timothy R Sterling Richard D Moore Parastu Kasaie The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. PLoS Medicine |
| title | The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. |
| title_full | The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. |
| title_fullStr | The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. |
| title_full_unstemmed | The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. |
| title_short | The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study. |
| title_sort | forecasted prevalence of comorbidities and multimorbidity in people with hiv in the united states through the year 2030 a modeling study |
| url | https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1004325&type=printable |
| work_keys_str_mv | AT kerinalthoff theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cameronstewart theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT elizabethhumes theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT lucasgerace theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cynthiaboyd theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT kellygebo theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT amycjustice theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT emilyphyle theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT sallybcoburn theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT raynelllang theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT michaeljsilverberg theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT michaelahorberg theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT vivianedlima theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT mjohngill theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT mailekarris theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT peterfrebeiro theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT jenniferthorne theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT ashleighjrich theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT heidicrane theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT marikitahata theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT annarubtsova theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cherisewong theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT seanleng theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT vincentcmarconi theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT gypsyamberdsouza theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT hyangninakim theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT sonianapravnik theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT kathleenmcginnis theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT gregorydkirk theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT timothyrsterling theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT richarddmoore theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT parastukasaie theforecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT kerinalthoff forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cameronstewart forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT elizabethhumes forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT lucasgerace forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cynthiaboyd forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT kellygebo forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT amycjustice forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT emilyphyle forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT sallybcoburn forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT raynelllang forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT michaeljsilverberg forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT michaelahorberg forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT vivianedlima forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT mjohngill forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT mailekarris forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT peterfrebeiro forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT jenniferthorne forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT ashleighjrich forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT heidicrane forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT marikitahata forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT annarubtsova forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT cherisewong forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT seanleng forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT vincentcmarconi forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT gypsyamberdsouza forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT hyangninakim forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT sonianapravnik forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT kathleenmcginnis forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT gregorydkirk forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT timothyrsterling forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT richarddmoore forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy AT parastukasaie forecastedprevalenceofcomorbiditiesandmultimorbidityinpeoplewithhivintheunitedstatesthroughtheyear2030amodelingstudy |